Adherium Taps Nektar’s Former BD Exec To Head New North America Unit
This article was originally published in Clinica
Executive Summary
Adherium, the developer of the SmartInhaler technology for improving medication adherence in patients with chronic respiratory disorders, has appointed James Hattersley senior vice-president of business development, North America. Hattersley joins from US pharm firm Nektar Therapeutics, where he held a similar position. He will leverage his experience in identifying opportunities for commercial partnerships and strategic alliances to expand Adherium’s presence in the US and Canada. His appointment coincides with the opening of the company’s new San Francisco, California subsidiary serving that region, Adherium North America, Inc. Australian Stock Exchange-listed Adherium’s Smartinhaler platform comprises a range of approved Smartinhaler medication sensors which attach to prescription inhalers, and the SmartinhalerLive software, which integrates the data from the Smartinhalers into a usable form via communications protocols, mobile applications and cloud based software. The company teams up with pharma players, an example being AstraZeneca, with whom Adherium entered a long-term partnership last year to supply new devices and sensors to incorporate within global patient support programs for patients with COPD and asthma.